Lava Therapeutics Nv Reports Results For The Quarter Ended March 31: Earnings Summary

LAVA Therapeutics NV

19/05/2025 14:32

LAVA Therapeutics NV LVTX.OQ reported a quarterly adjusted loss of 13 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -2 cents.  The mean expectation of four analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -41 cents to -34 cents per share.

Reported revenue was zero​; analysts expected zero.

LAVA Therapeutics NV's reported EPS for the quarter was a loss of 13 cents​.

The company reported a quarterly loss of $3.48 million.

LAVA Therapeutics NV shares had fallen by 1.6% this quarter and gained 31.4% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 20.8% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for LAVA Therapeutics NV is $1.50

This summary was machine generated from LSEG data May 19 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.38
-0.13
Beat
Dec. 31 2024
-0.29
-0.14
Beat
Sep. 30 2024
-0.33
-0.46
Missed
Jun. 30 2024
-0.36
-0.31
Beat